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Previous gene function analyses have indicated that HOXA9, DEK, CBL and CSF1R are aberrantly
expressed in acute myeloid leukemia (AML). We analyzed the expression of these genes in a series of
41 adult patients with AML using quantitative real-time RT-PCR, and tested the association of the
expression with the following hematologic and clinical parameters: age, FAB, immunophenotype and
karyotype aberrations. A high proportion of the patients showed over- or underexpression of the
analyzed genes. DEK was overexpressed in 98% of the cases, whereas CBL, CSF1R and HOXA9 were
either overexpressed in 20%, 17% and 78% or underexpressed in 20%, 42% and 15% of the cases,
respectively. Patients whose karyotype contained t(8;21)(q22;q22), showed lower relative expression
of HOXA9 at a statistically significant level ð p , 0:05Þ: Bone marrow samples without expression of
CD34 antigen were associated with either overexpression of DEK or HOXA9. Furthermore, an
association was found between the AML-M2 subtype and lower expression of CBL, CSF1R or HOXA9,
and between the AML-M5 subtype and CBL or CSF1R overexpression.
Keywords: Quantitative real-time RT-PCR; Acute myeloid leukemia; Gene expression; Array-based
methods
INTRODUCTION
The array-based methods have revealed a great amount
of new information of genes expressed in acute myeloid
leukemia (AML) [1,2]. In this study, we selected four
genes that were previously detected to be aberrantly
expressed in AML by array techniques: homeobox
protein hox-a9 (HOXA9), dek oncogene (DEK),
macrophage colony stimulating factor I receptor
precursor (CSF1R) and c-cbl protooncogene (CBL)
(Table I).
HOXA9 is a transcriptional factor potentially associated
in myeloid differentiation. The chromosomal transloca-
tion t(7;11)(p15;p15), which involves a fusion between
HOXA9 and the nucleoporin NUP98 resulting in the
inhibition function of HOXA9, is present in a small subset
of AML patients with poor prognosis [3,4].
DEK is a nuclear protein, with both RNA and DNA
binding properties, expressed in many tissues [5,6]. This
gene is implicated in a subset of AML carrying the
t(6;9)(p23;q34) in which the DEK-CAN protein confers
poor prognosis [7,8].
CBL protooncogene product participates in signal
transduction of hematopoietic cells [9]. CBL generates
negative regulation of CSF-1 by binding and stimulating
CSF1R ubiquitination, which increases the endocytic rate
of CSF1R and reduces the signal of activated receptors on
cell membrane [10].
The expression of the four genes in 41 AML patients at
diagnosis was studied using quantitative real-time reverse
transcription polymerase chain reaction (QRT-PCR).
Furthermore, we analyzed whether aberrant expression
of these genes was associated with hematologic,
cytogenetic or clinical parameters.
ISSN 1042-8194 print/ISSN 1029-2403 online q 2003 Taylor & Francis Ltd
DOI: 10.1080/1042819031000119299
*Corresponding author. Address: Department of Medical Genetics, POB 21 (Haartmaninkatu 3, 4th floor), FIN-00014 University of Helsinki,
Helsinki, Finland. Tel.: þ358-9-191-26527. Fax: þ358-9-191-26788. E-mail: sakari.knuutila@helsinki.fi
Leukemia & Lymphoma, Vol. 44, No. 11 (November 2003), pp. 1935–1941
MATERIALS AND METHODS
Patients
Bone marrow samples were obtained from 41 adult
patients with AML at the time of diagnosis. Fourteen of
the 41 patients (patients 1–14) belonged to the AML-99
protocol of the Catalan Group of Study and Treatment of
AML (CETLAM). The remaining 27 patients (patients
15–41) were diagnosed and treated according to the
protocol of the Department of Medicine, Helsinki
University Central Hospital. Patients nos 15–29 had
previously undergone cDNA array analysis as reported
by Larramendy et al. [2] Table II summarizes the
laboratory and clinical data of the patients. Two bone
marrow aspirates from healthy donors were included as
controls.
RNA Extraction
Total RNA was extracted from bone marrow samples
according to standard protocol, as described previously
[2]. DNase treatment of total RNA was performed
according to the Atlas cDNA expression array’s user
manual (Clontech Laboratories Inc., Palo Alto, CA, USA).
The quality and the integrity of the RNA were checked on
1% agarose gel after electrophoresis.
cDNA Synthesis
cDNA synthesis was performed from total RNA by using
1st Strand cDNA Synthesis Kit for RT-PCR (AMV)
(Roche Diagnostics GmbH, Mannheim, Germany)
according to the manufacturer’s instructions.
Real-time Quantitative RT-PCR
The oligonucleotide primers were designed and produced
by TIB MolBiol (Berlin, Germany) (Table III). Primers
were tested versus the BLAST algorithm (http://www.
ncbi.nlm.nih.gov/BLAST) to confirm the specific ampli-
fied product.
Quantitative gene expression analysis of four AML-
related genes and one housekeeping gene, beta-actin
(ACTB) was performed. QRT-PCR was carried out using
LightCycler FastStart DNA Master SYBR Green I and
LightCycler Instrument (Roche), as described previously
[2]. Four dilutions of beta-globulin gene (DNA Control
kit; Roche), from 0.015 to 15 ng/ml, were used to acquire
the standard curve in each experiment. In every assay,
runs were independently repeated two times and a
negative control was included. The amplification of PCR
products was verified using the melting curve analysis
option. Data analysis was performed using the Light-
Cycler Software Version 3.5.
The housekeeping gene ACTB was used as reference
against which the expression level of the transcript genes
of interest was normalized. For every sample, the target
mRNA copy number was divided by the ACTB mRNA
copy number to obtain a normalized target/ACTB value.
This value was then divided by the average normalized
target/ACTB value of the normal bone marrow samples
to obtain the relative target value [11]. Relative
expression levels higher than 3 were considered to
indicate overexpression, and lower than 0.3
underexpression.
Statistical Analysis
Statistical analysis was performed using SPSS for
Windows (Version 10.0). After the normalization of
expression values, the Kaplan–Meier analysis was used
to estimate survival distributions, and log-rank test
to evaluate significant differences among survival
curves [12]. Clinical and biological parameters
were compared using the Mann–Whitney U Test.
The chosen level of significance was 0.05, unless
otherwise indicated.
RESULTS
HOXA9, DEK, CBL and CSF1R quantification data
obtained using the LightCycler software were normalized
using the ACTB housekeeping gene. Gene expression in
the AML patients was compared to that in the normal bone
marrow samples (Table IV).
TABLE I Features of genes included in quantitative expression analysis
Genes mRNA Gene Bank accession number Chromosomal location
Blood disorder proteins
DEK protein X64229 6p23
Oncogenes and protein kinases activated in hematopoietic cells
C-cbl protooncogene X57110 11q23.3
Macrophage colony stimulating factor I receptor precursor (CSF-1-R) X03663 5q33.3-35
Transcriptor factor
Homeobox protein hox-a9 (HOXA9) U82759 7p15-p14
Housekeeping gene
Cytoplasmatic beta-actin (ACTB) X00351 7p15-p12
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GENE EXPRESSION OF HOXA9, DEK, CSF1R AND CBL IN AML 1937
HOXA9 was overexpressed in 32 cases (78%) and
underexpressed in 6 patients (14.6%), whereas no altered
expression was observed in the remaining 3 patients
(7.3%). All but one of the patients (97.6%) showed
overexpression of DEK. Overexpression of CSF1R was
seen in 7 patients (17.1%), underexpression in 17 samples
(41.5%) and normal expression in 17 patients (41.5%).
CBL was overexpressed in 8 patients (19.5%) and
underexpressed in 8 patients (19.5%), whereas no altered
expression was observed in the remaining 25 patients
(61%).
Patients with t(8;21)(q22;q22) showed decreased
expression of HOXA9 ð p ¼ 0:004Þ: An association was
found between CD342 bone marrow samples and over-
expression of DEK ð p ¼ 0:01Þ and HOXA9 ð p ¼ 0:005Þ:
When FAB subtypes were considered, M2 was associated
with lower expression levels of CBL ð p ¼ 0:034Þ;
CSF1R ð p ¼ 0:034Þ and HOXA9 (0.045). In the M5
subtype, both CBL and CSF1R were overexpressed
( p ¼ 0:012 and p ¼ 0:021; respectively). No further
association was seen between gene expression and
clinical-pathological parameters (Table V). Nevertheless,
statistically significant associations were observed
between decreased expression of CBL and age older
than 60 years ð p ¼ 0:034Þ:
DISCUSSION
Gene expression profiles of HOXA9, DEK, CSF1R and
CBL studied by real-time QRT-PCR showed expression
changes in 92.7%, 97.6%, 58.5% and 39% of the cases,
respectively, confirming previous cDNA microarray
results [1,2].
Overexpression of HOXA9 transcript was observed in
nearly 80% of cases. This result verifies several previous
findings demonstrating enhanced expression of HOXA9
in bone marrow AML samples [1,13–15]. As over-
expression of the gene does not seem to be present in
acute lymphoblastic leukemia [16], it may be considered
as a genetic marker for AML. Detection of HOXA9
overexpression was an independent event from the
presence of t(7;11)(p15;p15), since none of the 41
patients included in the analysis showed this chromo-
somal rearrangement.
The present results reveal the overexpression of DEK
transcripts in the majority of AML cases (97.6%). This
finding confirms our previous results by cDNA array [2].
The results from the present study highlight the potential
role of DEK as a genetic marker in the initiation and
progression of AML. As none of the patients presented
t(6;9)(p23;q34) in their karyotype, the overexpression
of the gene resulted from a mechanism other
than translocation, as recently proposed by Larramendy
et al. [2].
Underexpression of CBL or overexpression of CSF1R
increases the ratio of activated receptors on cell
membrane [10]. Either under- or overexpression ofTA
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CBL or CSF1R was seen in 34% of the patients.
This group of patients may have an increased
proliferation signal to CSF1 stimulation [17]. An
association was observed between lower expression
levels of CBL and patient age older than 60 years. The
increased expression levels of CBL or CSF1R in the M5
subtype, the monocytic AML, is interesting as their
expression is normal in the myelomonocytic AML and
decreased in the M2 subtype.
Sauvageau et al. [18] demonstrated for the first time that
homeobox A genes are expressed in human CD34þ cells
and underexpressed in CD342 cells in normal bone
marrow samples. Kawagoe et al. [13] found consistent
results in normal bone marrow samples, but no difference
in HOXA9 expression between CD34þ and CD342 cells
was detected in AML bone marrow samples. According to
these previous reports, the present observation of
higher HOXA9 overexpression in CD342 AML samples
than in CD34þ AML samples may indicate deregulation
of HOXA9 expression during leukemogenesis.
In contrast, little is known about the phenotypic
expression of DEK in myeloid cells. Our CD342
AML samples showed higher DEK expression than
CD34þ AML samples, providing a clue to understand
its patterns of activation during leukemic cell
differentiation.
Lower relative amounts of HOXA9 were detected in
patients with t(8;21)(q22;q22) ð p ¼ 0:004Þ: Similarly,
Drabkin et al. [15] detected low homeobox (HOX) gene
expression in cases with prognostically favorable
cytogenetic features. This association suggests that
oncogenic proteins produced by a chromosomal trans-
location, such us AML1-ETO in t(8;21)(q22;q22), affect
HOX gene expression, altering the transcription function
and disrupting myeloid cell differentiation at different
linages [19].
Although HOXA9 overexpression has been shown to
correlate with treatment failure in AML [1], extended
studies have not been able to reveal any significant
associations with complete response rates or event-free
survival [15]. Whether the expression status of HOXA9 in
our patients has any prognostic value is an issue that we
will study once the follow-up time is long enough to
provide statistical power to the analysis.
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TABLE IV QRT-PCR results as relative expression level
Relative expression level* DEK n (%) CBL n (%) CSF1R n (%) HOXA9 n (%)
Overexpression 40 (97.6) 8 (19.5) 7 (17.1) 32 (78)
3 to 10 2 (4.9) 6 (14.6) 4 (9.7) 2 (4.9)
11 to 100 14 (34.1) 2 (4.9) 1 (2.4) 4 (9.7)
101 to 1000 13 (31.7) – 2 (4.9) 15 (36.6)
1001 to 10000 10 (24.4) – – 6 (14.6)
10001 to 100000 1 (2.4) – – 6 (14.6)
. 100000 – – – 1 (2.4)
Normal expression 1 (2.4) 25 (61) 17 (41.5) 3 (7.3)
Underexpression – 8 (19.5) 17 (41.5) 6 (14.6)
0.3 to 0.1 – 6 (14.6) 12 (29.3) 2 (4.9)
0.09 to 0.01 – 2 (4.9) 4 (9.7) 2 (4.9)
0.009 to 0.001 – – 1 (2.4) 2 (4.9)
Bold type, high frequencies for each gene.
* Relative expression level .3 was considered to indicate overexpression and ,0.3 underexpression.
TABLE III Primers
Sequence 50-30 F Length CG Tm Product
Gene R Position (pb) (%) (8C) size (bp)
ACTB AgCCTCgCCTTTgCCgA 23F 17 64.7 68.5 174
CTggTgCCTggggCg 196R 15 80.0 64.1
DEK gTgggTCAgTTCAgTggC 412F 18 61.1 61.9 291
AggACATTTggTTCgCTTAg 702R 20 45.0 60.7
CSF1R CACCAAgCTCgCAATCCCTC 1015F 20 60.0 63.7 169
CTCTACCACCCggAAgAACA 1183R 20 55.5 63.9
CBL ATgTCCCAAAgCCACCTg 2472F 18 55.6 63.6 217
gCAggACCACTACCTTgCT 2688R 19 57.9 61.9
HOX9A AAAAATCTACCTgTTCCTgAC 1174F 21 38.1 56.3 236
CTATCTTCCACAATCACAATggg 1409F 23 43.5 64.1
F, forward; R, reverse; Tm, melting temperature.
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